168 related articles for article (PubMed ID: 30811287)
1. Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows.
Regan MM; Fleming GF; Walley B; Francis PA; Pagani O
J Clin Oncol; 2019 Apr; 37(11):862-866. PubMed ID: 30811287
[No Abstract] [Full Text] [Related]
2. The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer.
Mukai H; Aihara T; Yamamoto Y; Takahashi M; Toyama T; Sagara Y; Yamaguchi H; Akabane H; Tsurutani J; Hara F; Fujisawa T; Yamamoto N; Ohsumi S;
Breast Cancer; 2015 Jan; 22(1):5-15. PubMed ID: 25200171
[No Abstract] [Full Text] [Related]
3. Ribociclib in HR-positive, HER2-negative breast cancer.
Burki TK
Lancet Oncol; 2016 Nov; 17(11):e482. PubMed ID: 27746106
[No Abstract] [Full Text] [Related]
4. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Harris LN; Ismaila N; McShane LM; Andre F; Collyar DE; Gonzalez-Angulo AM; Hammond EH; Kuderer NM; Liu MC; Mennel RG; Van Poznak C; Bast RC; Hayes DF;
J Clin Oncol; 2016 Apr; 34(10):1134-50. PubMed ID: 26858339
[TBL] [Abstract][Full Text] [Related]
5. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
Colleoni M; Munzone E
Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
[TBL] [Abstract][Full Text] [Related]
6. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
7. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
8. What is the value of the 21 gene recurrence score in HER2-negative patients?
Rosman M; Mylander WC; Tafra L
J Clin Oncol; 2010 Nov; 28(31):e647; author reply e648. PubMed ID: 20876423
[No Abstract] [Full Text] [Related]
9. Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.
Regan MM; Francis PA; Pagani O; Fleming GF; Walley BA; Viale G; Colleoni M; Láng I; Gómez HL; Tondini C; Pinotti G; Price KN; Coates AS; Goldhirsch A; Gelber RD
J Clin Oncol; 2016 Jul; 34(19):2221-31. PubMed ID: 27044936
[TBL] [Abstract][Full Text] [Related]
10. [Adjuvant chemotherapy of early stage breast cancer].
Boér K
Orv Hetil; 2010 Feb; 151(9):344-53. PubMed ID: 20159750
[TBL] [Abstract][Full Text] [Related]
11. [Modern pharmacological therapy of breast cancer].
Láng I; Kahán Z; Hitre E; Dank M; Rubovszky G; Horváth Z; Kásler M
Orv Hetil; 2012 Jan; 153(2):56-65. PubMed ID: 22217685
[TBL] [Abstract][Full Text] [Related]
12. Is breast conservation therapy superior to mastectomy for women with triple-negative breast cancers?
Pignol JP; Rakovitch E; Olivotto IA
J Clin Oncol; 2011 Jul; 29(21):2841-3. PubMed ID: 21670459
[No Abstract] [Full Text] [Related]
13. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.
Ilgun S; Sarsenov D; Erdogan Z; Ordu C; Celebi F; Nur Pilanci K; Ozturk A; Selamoglu D; Alco G; Aktepe F; Eralp Y; Tuzlali S; Ozmen V
J BUON; 2016; 21(6):1425-1432. PubMed ID: 28039703
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer biomarkers before and after neoadjuvant chemotherapy: does repeat testing impact therapeutic management?
Xian Z; Quinones AK; Tozbikian G; Zynger DL
Hum Pathol; 2017 Apr; 62():215-221. PubMed ID: 28041972
[TBL] [Abstract][Full Text] [Related]
15. Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy.
Chen S; Huang L; Chen CM; Shao ZM
Oncotarget; 2015 Jul; 6(20):18174-82. PubMed ID: 26053183
[TBL] [Abstract][Full Text] [Related]
16. Tumour epidermal growth factor receptor, erbB-2 and cathepsin D in node-negative invasive breast cancer: their impact on the selection of patients for systemic adjuvant therapy.
Tonkin KS; McKay JW; Stitt LW; Tokmakejian S; Haines DS
Cancer Prev Control; 1999 Apr; 3(2):131-6. PubMed ID: 10474760
[TBL] [Abstract][Full Text] [Related]
17. Potential therapeutic target for triple-negative breast cancer.
Gilbert JA
Lancet Oncol; 2012 Aug; 13(8):e330. PubMed ID: 23024992
[No Abstract] [Full Text] [Related]
18. Risk of recurrence estimates with IHC4+C are tolerant of variations in staining and scoring: an analytical validity study.
Dodson A; Zabaglo L; Yeo B; Miller K; Smith I; Dowsett M
J Clin Pathol; 2016 Feb; 69(2):128-35. PubMed ID: 26281860
[TBL] [Abstract][Full Text] [Related]
19. [Pharmaceutical therapy of breast cancer].
Láng I; Kahán Z; Pintér T; Dank M; Boér K; Pajkos G; Faluhelyi Z; Pikó B; Eckhardt S; Horváth Z
Magy Onkol; 2010 Sep; 54(3):237-54. PubMed ID: 20870601
[No Abstract] [Full Text] [Related]
20. Oncotype DX test on unequivocally HER2-positive cases: potential for harm.
Bhargava R; Dabbs DJ
J Clin Oncol; 2012 Feb; 30(5):570-1. PubMed ID: 22231038
[No Abstract] [Full Text] [Related]
[Next] [New Search]